Expansion of the board of directors

[et_pb_section fb_built=“1″ _builder_version=“3.22″][et_pb_row _builder_version=“3.25″ background_size=“initial“ background_position=“top_left“ background_repeat=“repeat“][et_pb_column type=“4_4″ _builder_version=“3.25″ custom_padding=“|||“ custom_padding__hover=“|||“][et_pb_text _builder_version=“4.4.8″]

HAEMATO AG: Expansion of the board of directors: Strengthening the strategic and operative implementation of the product business in the Haemato Group

Schönefeld, 30.11.2020 – The supervisory board of HAEMATO AG has appointed Mr. Patrick Brenske to the board of directors of HAEMATO AG at its meeting today.

With immediate effect Mr. Patrick Brenske will take over the responsibility for the product business as well as for purchasing and sales.

Until 2015 Mr. Brenske worked for the HAEMATO Group for about eight years as Head of Purchasing and Sales and laid the foundation for the product business of HAEMATO by obtaining the manufacturing license according to § 13 AMG.

The explicit focus and joint responsibility for the areas of purchasing and sales of the new Management Board will strengthen HAEMATO with regard to the optimal control of the existing product portfolio.


HAEMATO AG, founded in 1993, is a pharmaceutical company focusing on the growing markets of high-priced specialty pharmaceuticals in the indication areas of oncology and HIV as well as other chronic diseases.

HAEMATO AG is listed in the Basic Board (Open Market) of the Frankfurt Stock Exchange. Key figures on the HAEMATO AG share:
Subscribed capital: EUR 2,286,715
Listed class of shares: bearer ordinary shares
ISIN: DE000A289VV1
Stock exchange code: HAEK


Go back

For investors

Do you have any further questions about the group? Our investor relations team is happy to help you..

Contact us